FLASH NEWS LIVE

Novo Nordisk Addresses FDA Concerns with Action Plan

Novo Nordisk Addresses FDA Concerns with Action Plan

Novo Nordisk received a warning letter from the FDA regarding an inspection at its New Jersey site in early 2025. The company has initiated a corrective action plan, continuously updating the FDA. Despite a second letter concerning another site, Novo remains confident there will be no impact on production.

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
Instagram Meta X LinkedIn Whatsapp